Nuwiq® is contraindicated for patients who are hypersensitive to the active substance or to any ingredient in the formulation or component of the container.

• It is essential to confirm the deficiency of FVIII before starting treatment with Nuwiq®.
• Nuwiq® powder should be reconstituted according to directions and using only the supplied solvent (2.5 mL water for injection) and the supplied injection set to ensure optimal effectiveness and safety.
• Transmission of infectious viruses can result from use of contaminated needles or accidental puncture with contaminated needles.
• Strongly recommended that every time Nuwiq® is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
• All patients treated with Nuwiq® should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests
  Allergic-type hypersensitivity reactions are possible.
• Risk of central venous access device (CVAD)-related complications.
• Do not use this medicine after the expiry date stated on the label or if signs of deterioration of the tamper-proof packaging, especially of the syringe and/or the vial, are visible.
• Pregnant and Nursing Women: animal reproduction studies have not been conducted with Nuwiq® and it has not been used in women. Nuwiq® should be used during pregnancy and lactation only if clearly indicated.

Please consult the product monograph at https://www.octapharma.ca/en/therapies/product-overview/ for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed on this site. The product monograph is also available by calling us at 1-888-438-0488 or by contacting us via email: medinfo@octapharma.ca

Health professionals may report adverse reactions to adr.canada@octapharma.com.  You can also report any suspected Adverse Reactions directly to the Canada Vigilance Program (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html).